BriaCell Therapeutics Corp.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of BriaCell Therapeutics Corp. generated cash of -$24,126,128, which is less than the previous year. Cash used in financing activities reached the amount of $4,418,926 last year. Net change in cash is therefore -$20,389,003.
Cash Flow
| 2015 | -935.26K | -316.21K | 2.06M |
|---|---|---|---|
| 2016 | -1.19M | 158.78K | 801.89K |
| 2017 | -1.53M | 120.35K | 2.32M |
| 2018 | -3.80M | -453.62K | 4.06M |
| 2019 | -3.87M | 1.01M | 2.27M |
| 2020 | -1.15M | 0 | 1.07M |
| 2021 | -7.74M | 0 | 64.99M |
| 2022 | -12.48M | 0 | -3.74M |
| 2023 | -23.74M | 0 | 3.95M |
| 2024 | -24.12M | -681.80K | 4.41M |
BCTX Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 21.25M | 41.04M | 57.26M | 21.24K | 143.79K | 713.69K | 970.45K | 137.89K | 355.78K | 20.03K |
Operating activities | ||||||||||
Net income | -4.93M | -20.30M | -26.83M | -428.33K | -3.68M | -4.40M | -4.15M | -2.58M | -1.69M | -2.68M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 83.89K | 15.27K | 15.27K | 15.25K | 13.96K | 14.25K | 12.96K | 232 | 907 | 434 |
Stock-based compensation expense | 1.80M | 2.19M | 3.07M | 1.96M | 1.68K | 46.07K | 0 | 218.24K | 496.20K | 396.86K |
| Deferred income tax benefit | 1.80M | 2.19M | 3.07M | 1.96M | 1.68K | 46.07K | 0 | 218.24K | 496.20K | 396.86K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 5.31K | -11.43K | 10.14K | -18.06K | 11.81K | -11.99K | -2.80K | 24.38K | -19.59K |
Inventories | 0 | -5.31K | 11.43K | -10.14K | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 6.04M | 660.45K | 249.16K | -1.40M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -24.12M | -23.74M | -12.48M | -7.74M | -1.15M | -3.87M | -3.80M | -1.53M | -1.19M | -935.26K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | -453.62K | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -456.80K | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.74K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 531.08K |
Cash generated by investing activities | -681.80K | 0 | 0 | 0 | 0 | 1.01M | -453.62K | 120.35K | 158.78K | -316.21K |
Financing activities | ||||||||||
Common Stock Issued | 4.41M | 4M | 0 | 51.62M | 1.05M | 2.42M | 3.32M | 2.44M | 799.14K | 1.55M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -47.29K | -13.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -548.64K | -355.97K | -95.67K | 0 | 0 | 0 | 0 |
Cash used in financing activities | 4.41M | 3.95M | -3.74M | 64.99M | 1.07M | 2.27M | 4.06M | 2.32M | 801.89K | 2.06M |
Net Change In Cash | -20.38M | -19.79M | -16.22M | 57.24M | -124.34K | -566.97K | -250.19K | 876.61K | -224.21K | 337.19K |
Cash at end of period | 862.08K | 21.25M | 41.04M | 57.26M | 19.45K | 146.71K | 720.25K | 1.01M | 131.57K | 357.23K |
| Data source | Data source | Data source |